

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

ANNEX

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

(1) the following entries are inserted:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors and ATE	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
'007-030100-3	boric acid ...% [C ≤ 70 %]	231-714	47697-37	Tox. Liq. 3 Acute Tox. 3 Skin Corr. 1A	H272 H331 H314	GHS03 GHS06 GHS05 Dgr	H272 H331 H314	EUH070	Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 %	B'
'014-048100-6	silicon carbide fibres (with diameter < 3 µm, length > 5 µm and aspect ratio ≥ 3:1)	206-994	489-21308076	Carc. 1B	SI350i	GHS08 Dgr	H350i			

Status: Point in time view as at 19/05/2020.**Changes to legislation:** There are currently no known outstanding effects for the
Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

'014-04	49-00-00-20-44-2868-02	49-00-00-20-44-2868-02	49-00-00-20-44-2868-02	2868-02	Skin Sens. 1B	H317	GHS07 Wng	H317'			
'014-05	50-00-06-213-934-067-534	50-00-06-213-934-067-534	50-00-06-213-934-067-534	067-534	Repr. Irrit. 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane	H360FD	GHS08 Dgr	H360FD'			
'016-09	98-00-01-210-871624-92	98-00-01-210-871624-92	98-00-01-210-871624-92	1624-92	Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410	GHS02 GHS06 GHS08 GHS09 Dgr	H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410		inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/ kg bw M = 1 M = 10'	
'029-02 X	24-00-01-0231-159744-50	24-00-01-0231-159744-50	24-00-01-0231-159744-50	159744-50	Aquatic Chronic 2	H411	GHS09	H411'			

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the
 Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

'029-025-005	239-703-42600-189-8	15627-005-1	342600-189-8	Hydroxy-N-nitrosocyclohexylamine; bis(N-cyclohexyl-diazonium-dioxy)-copper; [Cu-HDO]	Acute Oral (liver); Tox. 4; STOT RE 2; Eye Dam. 1; Aquatic Acute 1; Aquatic Chronic 1	H228 H302 H373 H318 H400 H410	GHS02 GHS07 GHS08 GHS05 GHS09 Dgr	H228 H302 H373 (liver) H318 H410	oral: ATE = 360 mg/ kg bw M = 1 M = 1'	
'050-031-009	122-883-648-188-1	[1] 293-909-5648-391-0	[1] [2]	dilaurate [1] stannane [2] dioctyl-, bis(cocoacyloxy) derivs. [2]	Repr. 1B; STOT RE 1	H360D H372 (immune system)	GHS08 Dgr	H360D H372 (immune system)'		
'601-091-000	205-884-1330-0	115-237-858-2	115-237-858-2	dibenzo[a,l]pyrene	Carc. 1B; Muta. 2	H350 H341	GHS08 Dgr	H350 H341	Carc. 1B; H350: C ≥ 0,001 %'	
'603-237-003	125225-128-7	115850-19-6	115850-19-6	azole (ISO); (1RS,2SR,5RS; 1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentane	Tox. 4; STOT RE 2; Aquatic Chronic 1	H360D H302 H373 (eyes, skin, liver) H410	GHS08 GHS07 GHS09 Dgr	H360D H302 H373 (eyes, skin, liver) H410	oral: ATE = 500 mg/ kg bw M = 100'	
'603-238-009	205-594-473-24	115-237-858-2	115-237-858-2	(2-methoxyethoxy)ethyl ether; tetraglyme	Repr. 1B	H360FD	GHS08 Dgr	H360FD'		
'603-239-004	76738-028-0	115850-19-6	115850-19-6	utrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-	Repr. 2; Acute Tox. 4	H361d H332 H302 H319 H400 H410	GHS08 GHS07 GHS09 Wng	H361d H332 H302 H319 H410	inhalation: ATE = 3,13 mg/L (dusts)	

*Status: Point in time view as at 19/05/2020.**Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)*

	(1 <i>H</i> -1,2,4-triazol-1-yl)pentan-3-ol			Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1					or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10'
'603-240-20-X	221-967-296-90	221-967-296-90	221-967-296-90	Carc. 1B Mut. 3B	H350 H340	GHS08 Dgr	H350 H340'		
'603-240-20-X	221-967-296-90	221-967-296-90	221-967-296-90	Skin Sens. 1	H317	GHS07 Wng	H317'		
'605-042-00-3	201-288-88-54-6	201-288-88-54-6	201-288-88-54-6	Repr. 1B	H360FD	GHS08 Dgr	H360FD'		
'607-734-00-3	246-831-243-19-90	246-831-243-19-90	246-831-243-19-90	Acute Tox. 4 STOT RE. 2 Aquatic Acute Aquatic Chronic 1	H302 H373 (liver) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (liver) H410	oral: ATE = 450 mg/kg bw M = 10 M = 10'	
'607-740-00-3	248-523-255-4-26	248-523-255-4-26	248-523-255-4-26	Repr. 1B	H360FD	GHS08 Dgr	H360FD'		
'607-744-00-4	951659-40-8	951659-40-8	951659-40-8	Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H302 H373 (muscle) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (muscle) H410	oral: ATE = 500 mg/kg bw M = 10 M = 10'	

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

'607-740-00-X	40-00-carbazone-317815-8			Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1000 M = 1000'	
'607-740-00-5	201-19672-33-4			Skin Corr. 1C Eye Dam. 1	H314 H318	GHS05 Dgr	H314	EUH071'		
'607-740-00-0	221-4993-21-6			Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1	H226 H341 H360FD H331 H302 H314 H318 H317	GHS02 GHS05 GHS06 GHS08 Dgr	H226 H341 H360FD H331 H302 H314 H317	EUH071	Inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/ kg bw'	
'607-740-00-6	1206-05829-12-5			Eye Dam. 1 Skin Sens. 1B	H318 H317	GHS05 GHS07 Dgr	H318 H317			B'

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

'607-746-00-1	274-357-0161-423c.1	423c.1	BI350	GHS08	H350		inhalation:
<i>N</i> - (hydroxymethyl)glycinate; [formaldehyde released from sodium <i>N</i> - (hydroxymethyl)glycinate]			Muta. H341 H332 Acute Tox. 4 H315 Acute Tox. H319 H317	Dgr	H341 H332 H302 H335 H315 H319 H317		'ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/ kg bw
'611-181-00-5	66603-10-0	10-0	H228	GHS02	H228		oral:
(oxido- <i>NNO</i> - azoxy)cyclohexane; cyclohexylhydroxydiazole 1- oxide, potassium salt; [K- HDO]			Sol. 1 H301 Acute Tox. 3 H315 STOT RE 2 H411 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2	Dgr	H301 H373 (liver) H315 H318 H411 H301 H373 (liver) H315 H318 H411		'ATE = 136 mg/ kg bw'
'612-294-00-3	0221106-506-10	506-10	H314	GHS05	H314	EUH07	M =
etilsulfate; <i>N</i> - ethyl- <i>N,N</i> - dimethylhexadecan-1- aminium ethyl sulfate; mectronium ethyl sulphate; [MES]			Corr. 1 H318 H400 H410 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	Dgr	H410 H410		100 M = 1000'
'613-330-00-62-	141778-2103-6	2103-6	H317	GHS07	H317		M = 1
[4-(4- chlorophenoxy)-2-			Sens. H400 H410	Wng	H410		M = 1'

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

	(trifluoromethyl)phenyl-1 <i>H</i> -1,2,4-triazol-1-yl)propan-2-ol;			Aquatic Acute 1 Aquatic Chronic 1				
'613-33001	lapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1 <i>H</i> -pyrazol-1-yl]ethanone	10033	8670	Aquatic Chronic 1 H410	GHS09 Wng	H410		M = 1'
'613-33007	zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyrithionato-.kappa.S]zinc	236-671	3463-4	Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H360D H330 H301 H372 (H372)8 H400 H410	GHS08 GHS06 GHS05 GHS09 Dgr	H360D H330 H301 H372 H318 H410	inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10'
'613-33100	3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]piperidin-2-one	26266	3213-2	Repr. 1B Acute Tox. 4 Skin Irrit. 1	H360FD H302 H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H360FD H302 H317 H410	oral: ATE = 500 mg/kg bw M = 100 M = 100'

*Status: Point in time view as at 19/05/2020.**Changes to legislation: There are currently no known outstanding effects for the
Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)*

				Aquatic Acute 1 Aquatic Chronic 1					
'613-335-00-8	264-843-8	359-8	1	Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H302 H314 H317 H410	EUH07	Inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/ kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100'
'613-335-00-3	2527-664	3	1	Acute Tox. 4 Acute Tox. 3	H312 H301 H314 H318 H317 H400	GHS06 GHS05 GHS09 Dgr	H312 H301 H314 H317 H410	EUH07	Dermal: ATE = 1100 mg/ kg bw

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

				Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2	H411				oral: ATE = 175 mg/ kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1'
'616-228-00-4	(difluoromethyl)-1-methyl- <i>N</i> -(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad	907204	31-8	Aquatic Acute 1 Aquatic Chronic 1	H362 H400 H410	GHS09 Wng	H362 H410		M = 1 M = 1'
'616-230-00-5	(hydroxymethyl)acrylamide; methylolacrylamide; [NMA]	213-10324-42	32-4	Carc. 1 Muta. 1B STOT RE 1	H350 H340 H372 (peripheral nervous system)	GHS08 Dgr	H350 H340 H372 (peripheral nervous system)'		
'616-233-00-0	fluoro-1,3-dimethyl- <i>N</i> -[2-(4-methylpentan-2-yl)phenyl]-1 <i>H</i> -pyrazole-4-carboxamide; 2'-[(<i>RS</i>)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen	494793	67-8	Aquatic Acute 1 Aquatic Chronic 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M = 1 M = 1'
'616-235-00-6	dicarb (ISO); isopropyl [(2 <i>S</i>)-3-methyl-1- $\{$ 1-(4-	140923	67-7	Carc. 2	H351	GHS08 Wng	H351'		

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

	methoxyphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate								
'616-233-100-1'	Shufam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide	175217	2061	H373 H411	GHS08 GHS09 Wng	H373 H411'			
'650-057-006-233-644-87696-253-1'	Mungo ext. [cold-pressed oil of <i>Azadirachta indica</i> seeds without shells extracted with super-critical carbon dioxide]	83-644-87696-253-1	253-1	H412		H412'			

- (2) the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:

Index No	Chemical name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram Signal Word Code(s)	Hazard Suppl. statement Code(s)	Hazard M-factors and ATE	
'007-004-00-1'	acid ...% [C > 70 %]	231-714	7897-370	Tox. Liq. 2 Acute Tox. 1 Skin Corr. 1A	H272 H330 H314	GHS03 GHS06 GHS05 Dgr	H272 H330 H314	EUH070	Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 %

*Status: Point in time view as at 19/05/2020.**Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)*

	diocetyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]			Aquatic Acute 1 Aquatic Chronic 1	H400 H410		H410'		
'082-01	100-1 powder; [particle diameter < 1 mm]	231-100	7439-9	Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1	H360FD H362 H400 H410	GHS08 GHS09 Dgr	H360FD H362 H410	Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10'	
'603-01	100-0 butoxyethanol; ethylene glycol monobutyl ether	203-905	5-D1-76	Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2	H332 H302 H315 H319	GHS07 Wng	H332 H302 H315 H319	oral: ATE = 1200 mg/kg bw'	
'603-06	65-00-9 bis(2,3-epoxypropoxy)resorcinol diglycidyl ether	202-987	61-90	6. Carc. 1 Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3	H350 H341 H311 H302 H315 H319 H317 H412	GHS08 GHS06 Dgr	H350 H341 H311 H302 H315 H319 H317 H412	dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw'	
'607-17	70-00-0 methyl (ISO);	101-190	01200	STOT RE 2	H373 H317 H400	GHS08 GHS07 GHS09	H373 H317 H410	M = 100	

*Status: Point in time view as at 19/05/2020.**Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)*

				Aquatic Chronic 1					
'613-11	20065-247-76	26530-20	20065-247-76	26530-20	Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H330 H311 H301 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H311 H301 H314 H317 H410	EUH07 Inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/ kg bw oral: ATE = 125 mg/ kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100'
'613-11	5006-233-000	16004-4	5006-233-000	16004-4	Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2	H361d H302 H318 H317 H411	GHS08 GHS07 GHS05 GHS09 Dgr	H361d H302 H318 H317 H411	oral: ATE = 1600 mg/ kg bw'
'613-11	25006-78587-	0500-	25006-78587-	0500-	Aquatic Acute 1	H400 H410	GHS09 Wng	H410	M = 1 M = 1'

Status: Point in time view as at 19/05/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)

	cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide			Aquatic Chronic 1					
'613-20	2004 pyrothiazine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one	123312	89-02	Repr. 2 Aquatic Chronic 1	H351 H361fd H410	GHS08 GHS09 Wng	H351 H361fd H410		M = 1'
'613-20	5006 (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate	428-7907	2963-72	Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Chronic 1	H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410	GHS08 GHS07 GHS09 Wng	H351 H332 H302 H371 (nervous system; oral, inhalation) H410		inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10'
'616-01	4001 oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime	202-4906	29-7	Carc. 1 Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2	H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317	GHS08 GHS06 GHS05 Dgr	H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317		dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw'

*Status: Point in time view as at 19/05/2020.**Changes to legislation: There are currently no known outstanding effects for the
Commission Delegated Regulation (EU) 2020/1182. (See end of Document for details)*

				Eye Dam. 1 Skin Sens. 1					
'617-006-00-201-2780-43-3 X	617-006-00-201-2780-43-3 (o,o-dimethylbenzyl) peroxide			Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2	H242 H360D H315 H319 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H242 H360D H315 H319 H411'		

- (3) the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.

Status:

Point in time view as at 19/05/2020.

Changes to legislation:

There are currently no known outstanding effects for the Commission Delegated Regulation (EU) 2020/1182.